headshot
  • Dr Larry Weiss

    Chief Medical Officer
    AOBiome

Larry Weiss MD is the Chief Medical Officer at AOBiome. He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a number of patents and is published in the areas of chemistry, electrophysiology, and microbiology.  Dr. Weiss is the founder of CleanWell Company. 


julian
  • Professor Julian Marchesi

    Professor of Human Microbiome Research
    Cardiff University

Julian Marchesi graduated from Cardiff University with a PhD in biochemistry (1992) and became interested in the role bacteria play in ecosystem function. During his post-doctoral years he developed an interest in the contribution of uncultured microbes to the maintenance and function of ecosystems i.e. molecular microbial ecology. He subsequently secured a Wellcome Trust Fellowship which extended his molecular microbial ecology interest and investigated, with culture independent methods, the diversity and distribution of genes involved in biodegradation of priority pollutants in pristine environments. After a short time investigating the deep biosphere he obtained a Lectureship (2001) in the Department of Microbiology, University College Cork, Ireland where he transferred these “omic” skills into the human gut and started to investigate the human gut ecosystem in health and disease. After 7 years in UCC, he moved back to Cardiff University in 2008 to a senior lectureship, where he investigates the role of the gut microbiome in maintaining host health and initiating diseases not only of the gut, but throughout the host system.  In 2013 he was promoted to Reader and also took a half time Readership in Digestive Health at Imperial College London.


Johan_head
  • Johan E.T. van Hylckama Vlieg

    Vice President Microbiome & Human Health Innovation
    Chr. hansen A/S


KyleX1
  • David Kyle

    CEO
    BioSystems Inc.

Dr Kyle has been CEO of Evolve BioSystems Inc. since 2014. The company is focused on changing the standard of care of babies based on new understandings of the interrelationship between the baby, the baby’s microbiome, and mother’s milk. He previously acted as an advisor to bio-tech start-ups through the DJK Consulting, a firm he founded in 2010 after founding two biotech businesses of his own; Martek Biosciences and Advanced BioNutrition Corp. He has a PhD in Lipid Biochemistry from the University of Alberta and, in 2009, was inducted into the US Space Technology Hall of Fame for his contributions to science and industry.


head
  • Dr James Kinross

    Senior Lecturer in Colorectal Surgery
    Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery. He was awarded a Royal College of Surgeons of England training fellowship during his PhD and he was funded by the Academy of Medical Sciences as an early stage lecturer. He is a visiting Professor at the Royal College of Surgeons of Ireland. He is currently funded by Bowel and Cancer research and the Imperial BRC.


head
  • Professor David Berry

    Associate Professor Microbial Ecology
    University of Vienna

David Berry is Associate Professor at the University of Vienna. His research interests include:

  • Function of the intestinal microbiota in health and disease
  • Numerical approaches to study microbial communities 
  • Development of molecular and isotope-labeling methods for studying uncultivated microorganisms in their natural environment

He has 28 publications in peer-reviewed journals, including in leading multidisciplinary and discipline-specific journals such as: Proc Natl Acad Sci USA, Cancer Res, FEMS Microbiol Rev, and ISME J.


head
  • Dr David Cook

    Chief Scientific Officer
    Seres

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.